聚乙二醇重组人粒细胞集落刺激因子预防宫颈癌同步放化疗后中性粒细胞减少症的安全性及有效性分析

Safety and efficacy of polyethylene glycol recombinant human granulocyte colony-stimulating factor in concurrent chemoradiotherapy for cervical cancer

目的:探讨注射聚乙二醇重组人粒细胞集落刺激因子(PEG-rhG-CSF)治疗宫颈癌化疗所致中性粒细胞减少症的有效性和安全性。方法:筛选2016年1月-2018年12月来甘肃省肿瘤医院进行宫颈癌治疗的女性患者162例,随机分成对照组和治疗组。对照组79例,平均年龄为(38.7±3.6)岁;治疗组83例,平均年龄为(41.2±4.3岁)。2组皆进行同步放化疗,对照组患者化疗24 h注射重组人粒细胞集落刺激因子(rhG-CSF),治疗组患者化疗24 h后注射聚乙二醇重组人粒细胞集落刺激因子(PEG-rhG-CSF);2组患者化疗后定期复查血常规,检查骨髓抑制差异、中性粒细胞绝对值随时间变化差异、化疗延迟率及不良反应发生率。结果:治疗组给药后12~144 h中性粒细胞数与增殖率,化疗第一周期中性粒细胞数减少、白细胞减少方面均有显著差异(P<0.05);治疗组中性粒细胞数绝对值在不同时间点高于对照组,在给药第5、10天有显著性差异(P<0.05);另外治疗组的化疗延迟人数少于对照组(P<0.05);2组不良反应无显著差异(P>0.05)。结论:PEG-rhG-CSF在治疗宫颈癌同步放化疗中有较好的疗效和安全性。

OBJECTIVE To explore the efficacy and safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)injection in the treatment of chemotherapy-induced neutropenia in cervical cancer(CC).METHODS From January 2016 to December 2018,a total of 162 CC women were selected and divided into control(n=79)and experimental(n=83)groups.The average age was(38.7±3.6)years in control group(n=79)and(41.2±4.3)years in experimental group(n=83).Both groups received concurrent chemoradiotherapy.The control group received an injection of recombinant human granulocyte colony-stimulating factor(rhG-CSF)at 24 h after chemotherapy while the experimental group PEG-rhG-CSF 24 h later.Blood routine examination was performed regularly after chemotherapy for checking the changes of myelosuppression, absolute value of neutrophils with time, delayed rate of chemotherapy and incidence of adverse reactions.RESULTS Significant differences existed in count of neutrophils, proliferative rate, neutropenia and leukopenia in the first cycle of chemotherapy in experimental group at 12-144 h after dosing(P<0.05);absolute count of neutrophils was higher in experimental group than that in control group at different timepoints and significant differences existed at Day 5/10 post-dosing(P<0.05).Also the frequency of chemotherapeutic delay was less in experimental group than that in control group(P<0.05).No significant inter-group difference existed in adverse reactions.CONCLUSION PEG-rhG-CSF has excellent efficacy and safety in the treatment of cervical cancer with concurrent chemoradiotherapy.